Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

Item
http://www.wikidata.org/entity/Q33380788
Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSAVancomycin and nephrotoxicity: just another myth?Update on the safety of linezolid.Co-blockade of mecR1/blaR1 signal pathway to restore antibiotic susceptibility in clinical isolates of methicillin-resistant Staphylococcus aureus.Clinical update on linezolid in the treatment of Gram-positive bacterial infections.Antibacterial oxazolidinones: emerging structure-toxicity relationships.Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review.Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designLinezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment.The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: effect of additives on drug release rates and mechanical strength.Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial.Effect of linezolid on hematological and oxidative parameters in rats.Use of linezolid in neonatal and pediatric inpatient facilities--results of a retrospective multicenter survey.Pharmacokinetics of linezolid in plasma and cerebrospinal fluid in patients with cerebral hemorrhage post-surgical intervention.Negative impact of linezolid on human neutrophil functions in vitro.Pharmacokinetics and pharmacodynamics of linezolid in plasma/cerebrospinal fluid in patients with cerebral hemorrhage after lateral ventricular drainage by Monte Carlo simulation.
P2860

Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.

Item
http://www.wikidata.org/entity/Q33380788
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
@ast
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
@en
type
label
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
@ast
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
@en
prefLabel
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
@ast
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
@en
P1433
P1476
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698
P921
P356
P1433
P1476
Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.
@en
P2860
P2888
P304
P31
P356
10.2165/00002018-200831090-00004
P433
P478
P50
P577
P6179
P698
P921